Avalyn Pharma Inc.
Research Avalyn Pharma Inc. (AVLN) on Bullrun: market cap USD 1.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVLN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.14B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 28.94M
- Free cash flow-USD 26.35M
Valuation Snapshot
latest market cap is USD 1.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 85.20M | -USD 81.83M | n/a | -2.04 | USD 52.32M | USD 1.67M | -USD 238.66M |
| FY2024 | USD 0 | -USD 49.74M | -USD 48.46M | n/a | -1.19 | USD 23.96M | USD 0 | -USD 174.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.14B | n/a | n/a | n/a |
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avalyn Pharma Inc.'s market cap?
Avalyn Pharma Inc.'s market capitalization is USD 1.14B.
What does Avalyn Pharma Inc. do?
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.